Most Read Articles
4 days ago
In patients with type 2 diabetes, obesity may be protective against vision-threatening diabetic retinopathy, a recent Korea study has shown.
6 days ago
Atrial fibrillation (AF) carries an excess risk of stroke recurrence independent of comorbidity with and heart failure (HF), while HF without AF also poses a significant risk of recurrence, a study has shown.
Roshini Claire Anthony, 3 days ago

Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.

07 Jun 2019
Low-dose aspirin therapy does not confer significant benefits to elderly patients with hypertension, but treatment appears to increase the risk of haemorrhagic events, suggest a Japan study.

Albumin-bilirubin score predicts HCC occurrence after DAA treatment

02 Jun 2019

The albumin-bilirubin (ALBI) score, along with platelet count and aspartate aminotransferase-lymphocyte ratio (ALRI) index, is an effective and simple tool for identifying patients at risk of developing hepatocellular carcinoma (HCC) after treatment with direct-acting antivirals (DAA), a new study has found.

Researchers performed a retrospective cohort study including 514 cirrhosis patients scheduled for treatment with DAAs. Aside from ALBI score and ALRI index, baseline variables collected included neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII) and platelet-to-lymphocyte ratio (PLR).

Of the study participants, 416 did not have a previous diagnosis of HCC (median age at the start of therapy, 63.3 years; 58.2 percent male) while 98 did (median age at the start of therapy, 71.0 years; 61.2 percent male). The median follow-up time was 18.04 months.

Multivariable Cox regression analysis showed that ALBI score (hazard ratio [HR], 2.35, 95 percent CI, 1.05–5.25; p=0.038) and platelet count (HR, 0.92, 0.85–1.00; p=0.048) were both significantly and independently associated with the risk of HCC occurrence.

The cumulative hazards of HCC occurrence at 6, 12 and 18 months were 0.010, 0.050 and 0.072, respectively.

In comparison, ALRI index was the only pertinent factor for HCC recurrence in participants with a history of HCC (HR, 1.05; 1.01–1.09; p=0.007). In this group of patients, the cumulative hazards of recurrence at 6, 12 and 18 months were 0.074, 0.261 and 0.380, respectively.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
In patients with type 2 diabetes, obesity may be protective against vision-threatening diabetic retinopathy, a recent Korea study has shown.
6 days ago
Atrial fibrillation (AF) carries an excess risk of stroke recurrence independent of comorbidity with and heart failure (HF), while HF without AF also poses a significant risk of recurrence, a study has shown.
Roshini Claire Anthony, 3 days ago

Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.

07 Jun 2019
Low-dose aspirin therapy does not confer significant benefits to elderly patients with hypertension, but treatment appears to increase the risk of haemorrhagic events, suggest a Japan study.